Neuroinflammation and glial cell activation in mental disorders

Abstract

Mental disorders (MDs) are highly prevalent and potentially debilitating complex disorders which causes remain elusive. Looking into deeper aspects of etiology or pathophysiology underlying these diseases would be highly beneficial, as the scarce knowledge in mechanistic and molecular pathways certainly represents an important limitation. Association between MDs and inflammation/neuroinflammation has been widely discussed and accepted by many, as high levels of pro-inflammatory cytokines were reported in patients with several MDs, such as schizophrenia (SCZ), bipolar disorder (BD) and major depression disorder (MDD), among others. Correlation of pro-inflammatory markers with symptoms intensity was also reported. However, the mechanisms underlying the inflammatory dysfunctions observed in MDs are not fully understood yet. In this context, microglial dysfunction has recently emerged as a possible pivotal player, as during the neuroinflammatory response, microglia can be over-activated, and excessive production of pro-inflammatory cytokines, which can modify the kynurenine and glutamate signaling, is reported. Moreover, microglial activation also results in increased astrocyte activity and consequent glutamate release, which are both toxic to the Central Nervous System (CNS). Also, as a result of increased microglial activation in MDs, products of the kynurenine pathway were shown to be changed, influencing then the dopaminergic, serotonergic, and glutamatergic signaling pathways. Therefore, in the present review, we aim to discuss how neuroinflammation impacts on glutamate and kynurenine signaling pathways, and how they can consequently influence the monoaminergic signaling. The consequent association with MDs main symptoms is also discussed. As such, this work aims to contribute to the field by providing insights into these alternative pathways and by shedding light on potential targets that could improve the strategies for pharmacological intervention and/or treatment protocols to combat the main pharmacologically unmatched symptoms of MDs, as the SCZ.

The trajectory of putative astroglial dysfunction in first episode schizophrenia: A longitudinal 7-Tesla MRS study

“…In summary, this longitudinal 7T MRS study of ACC con rms the presence of reduced myo-inositol in the early stages of schizophrenia, that may progressively improve in patients who show symptomatic improvement. This supports the possibility of a putative astroglial de cit predating the rst presentation of psychosis, likely of early developmental 39 or of in ammatory 40 origin, but showing a trend of reversal with early intervention. Further, this also raises the need for experimental studies targeting the putative astroglial dysfunction, as this may improve clinical and functional outcomes in psychosis.…”

The Potential Role of COVID-19 in the Pathogenesis of Multiple Sclerosis—A Preliminary Report

“…As neurotropic viruses such as SARS-CoV-2 enter the CNS from the primary infection site, they invade the nervous tissues and disrupt its homeostasis, causing infections [ 24 ]. Inflammation of the CNS, known as neuroinflammation, includes both immunological and neuronal cells and results in a modulation of the immune response of the nervous system and synaptic plasticity [ 35 ]. The entry of SARS-CoV-2 into the CNS could occur via the hematogenous or peripheral nerve routes.…”

A system biology approach based on metabolic biomarkers and protein–protein interactions for identifying pathways underlying schizophrenia and bipolar disorder

“…and protein digestion/absorption pathway, which are important not only for the protein biosynthesis, but also for the functions interrelated with glucose metabolism, synthesis of neurotransmitters, and production of energy, whilst some of them have also the ability to modulate the inflammatory and immune systems. The association between MDs and inflammation/neuroinflammation has been widely discussed and accepted by many, and the correlation of pro-inflammatory markers with symptoms intensity was also reported in SCZ and BD 63 . Two other identified pathways are Hippo Signaling pathway and metabolism of xenobiotics by cytochrome p450 .…”